Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment
Titel:
Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment
Auteur:
Boertien, Tessel M. Drent, Madeleine L. Booij, Jan Majoie, Charles B.L.M. Stokkel, Marcel P.M. Hoogmoed, Jantien Pereira, Alberto M. Biermasz, Nienke R. Simsek, Suat Veldman, Ronald Groote Weterings, Annick J. Vink, Juan M. Tanck, Michael W.T. Fliers, Eric Bisschop, Peter H.